Advanced Genomic Analysis Technology to Support Genomics and Biomedical Genetics Research
CARLSBAD, Calif.--(BUSINESS WIRE)--The University of Cambridge and Life Technologies Corporation (NASDAQ:LIFE), announced today the formation of a collaboration to advance translational research studies in key disease areas such as cancer, diabetes and neurological disorders. Through this collaboration, next generation sequencing technology will be made available to the European research and clinical communities through the Eastern Sequence and Informatics Hub at Addenbrooke’s Hospital in Cambridge.
The Cambridge based hub was established with funding from the Medical Research Council and from the University’s Clinical School and NIHR Biomedical Research Centre to accelerate the use of genetic information to help identify new therapies, diagnostics and preventive strategies. Genomics and biomedical scientists will use three SOLiD™ 3 Plus Systems, next-generation DNA sequencing platforms from Life Technologies, to advance targeted medical resequencing and whole transcriptome analysis research studies.
“We are at an exciting point in history where technologies such as the SOLiD System, provide the throughput and accuracy required for comprehensive characterization of disease systems,” said Professor John Todd of the University of Cambridge and principal investigator at the Eastern Sequence and Informatics Hub, Addenbrooke’s Hospital. “The translation of this information into clinically relevant knowledge will have a direct impact on the treatment of human disease through the development of better diagnostic, prognostic and therapeutic agents.”
“The collaboration with the University of Cambridge’s Eastern Sequence and Informatics Hub, underlines our commitment to help deliver the potential of translational research and accelerate the realization of personalized medicine,” said Shaf Yousaf, President, Genomic Analysis at Life Technologies. “The SOLiD System offers an optimized and integrated next-generation sequencing solution to provide researchers with the required throughput, accuracy, speed and flexibility for a wide range of genetic investigations.”
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.
800 Years Transforming Tomorrow
The University of Cambridge was founded in 1209 and celebrates its 800th anniversary this year. Its mission is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. It is made up of 31 colleges and more than 100 departments that cater for some 12,000 undergraduate and 6,000 postgraduate students. In a beautiful setting by the River Cam, Cambridge is famed for the architecture of its historic colleges but also for its wealth of modern research and teaching facilities. The University’s reputation for outstanding academic achievement is known worldwide and reflects the intellectual achievement of its students, as well as the world-class original research carried out by the staff of the University and the Colleges. Some of the world’s most significant scientific breakthroughs have occurred at the University, including the splitting of the atom, invention of the jet engine and the discoveries of stem cells, plate tectonics, pulsars and the structure of DNA. From Isaac Newton to Stephen Hawking, the University has nurtured some of history’s greatest minds and has produced more Nobel Prize winners than any other UK institution with more than 80 laureates. Cambridge's great libraries and collections housed in eight world-class museums and in the colleges are scholarly resources of outstanding international significance.
Cambridge attracts the brightest and best students, researchers and academics from across the world, with a student population drawn from 135 different countries. www.cam.ac.uk
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
For Research Use Only. Not for use in diagnostic procedures.
